Skip to main content
MRKR logo

Marker Therapeutics, Inc.

MRKRNASDAQHealthcareBiotechnology

$1.07Today:- (-)1Y +7.58%

As of Oct 22, 2026 close

Market cap
$20.67M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.84$2.46
Volume (live)
-
Avg. volume (3M)
136.32K

Marker Therapeutics (MRKR) Income Statement

Marker Therapeutics reported revenue of $3.55M in fiscal 2025 (fiscal year ended Dec 31, 2025), down 46.2% from $6.59M a year earlier. Marker Therapeutics posted a net loss of $12.16M, compared with a net loss of $10.73M a year earlier. Gross margin was 100.0% and operating margin -363.5%.

Marker Therapeutics Income Statement Analysis

Values in millions USD

Scroll to see more
Marker Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Mar 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Revenue & Gross Profit
Revenue3.556.596.593.313.511.240.470.210.210.18
Cost of Revenue11.8013.4713.4710.4211.973.1618.8812.76124.005.25
Gross Profit3.55-6.886.593.319.01-1.92-18.41-12.55-123.79-5.07
Operating Expenses
Research & Development11.8013.4713.4710.4226.1427.7918.8812.76124.005.25
Selling, General & Administrative4.184.244.247.4811.349.7610.479.9824.386.41
Operating Expenses16.444.2417.7117.8938.9637.5610.479.98148.386.41
Operating Income-12.89-11.12-11.12-14.58-29.95-39.48-28.89-22.53-148.17-11.48
Other Income/Expense
Interest Income0.590.440.440.540.250.010.151.080.250.00
Interest Expense0.000.00-0.000.000.000.000.000.000.00
Other Income/Expense0.710.440.440.540.02-2.400.181.100.210.50
Income
Income Before Tax-12.18-10.68-10.68-14.04-19.78-41.88-28.71-21.43-147.96-10.98
Income Tax Expense-0.020.050.050.000.000.000.000.00-0.210.00
Net Income-12.16-10.73-10.73-8.24-29.93-41.88-28.71-21.43-147.96-10.98
Net Income - Continuous Operations-12.16-10.73-10.73-8.24-19.78-41.88-28.71-21.43-147.96-10.98
Net Income - Discontinued Operations---5.81-10.15-----
EBITDA-12.89-10.68-11.12-11.79-17.00-38.72-27.63-22.42-147.97-11.30
EBIT-12.44--11.12-14.58-19.79-39.48-28.89---
Depreciation & Amortization0.000.00-2.792.793.161.080.11148.1711.48
Earnings Per Share
Basic EPS-1.00-1.00-1.00-1.00-4.00-5.00-6.00-5.00-77.00-12.00
Diluted EPS-1.00-1.00-1.00-1.00-4.00-5.00-6.00-5.00-77.00-12.00
Basic Shares Outstanding15.318.988.988.818.357.654.704.561.910.95
Diluted Shares Outstanding15.318.988.988.818.357.654.704.561.910.95

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Marker Therapeutics Financial Statements

What was Marker Therapeutics's revenue in fiscal 2025?

Marker Therapeutics reported revenue of $3.55M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was down 46.2% from $6.59M a year earlier.

Is Marker Therapeutics profitable?

No. Marker Therapeutics reported a net loss of $12.16M in fiscal 2025. In fiscal 2024 it lost $10.73M.

What is Marker Therapeutics's operating margin?

Marker Therapeutics's operating income was −$12.89M on revenue of $3.55M in fiscal 2025, an operating margin of -363.5%, compared with -168.7% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition